172 results
8-K
EX-10.1
FENC
Fennec Pharmaceuticals Inc
21 Mar 24
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
4:02pm
generally applicable industry or self-regulatory standards, codes of practice and guidelines or other applicable matters of a similar nature, including … or technical nature which the disclosing Party or any of its Affiliates (the “Disclosing Party”) has supplied or otherwise made available to the other
424B7
FENC
Fennec Pharmaceuticals Inc
15 Mar 24
Prospectus with selling stockholder info
3:53pm
levels of expenditures;
the nature and scope of potential markets for PEDMARK®; and
our ability to attract and retain key employees.
The forward … property;
our corporate and development strategies;
our expected results of operations;
our anticipated levels of expenditures;
the nature and scope
8-K
EX-4.1
FENC
Fennec Pharmaceuticals Inc
5 Dec 23
Fennec Announces Incremental $5 Million Investment from Petrichor
8:51pm
or comparable payment obligation in connection therewith) exceeds $500,000.
13.7 Change in Nature of Business. The Company shall not, and the Company … of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does
8-K/A
EX-10.1
qpqmk
7 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:51am
8-K
EX-10.1
pjt6i5
4 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:58am
424B3
w5z m9atxzoog834ctq
15 Dec 22
Prospectus supplement
5:12pm